How Common Is Organ Damage from Cosentyx?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions, shows organ damage as rare in clinical data. Serious organ-specific adverse events occur in under 1% of patients across trials, with no single organ type dominating.[1][2]
Prescribing information lists hepatic events like elevated liver enzymes (up to 2.7% in trials, mostly mild and reversible) and rare cases of hepatitis. Renal issues, such as proteinuria, appear in <1% of cases. No routine cardiac or pulmonary organ toxicity is reported beyond hypersensitivity reactions.[3]
What Do Clinical Trial Data Show for Specific Organs?
In phase 3 trials (e.g., FUTURE, MEASURE programs with >10,000 patients):
- Liver: ALT/AST elevations in 2-3% (grade 1-2); serious hepatobiliary events in 0.1-0.3%.
- Kidney: Acute kidney injury or renal failure in <0.5%.
- Heart/Lungs: Inflammatory bowel disease (potential gut organ link) in 1-2%; cardiac events like myocarditis extremely rare (<0.1%).
- Other: No elevated risk for pancreatic or splenic damage.
Post-marketing surveillance reports isolated cases (e.g., interstitial lung disease, liver failure), but incidence remains <0.01% per patient-year.[2][4]
What Real-World Studies and Registries Say
Observational data from registries like SCULPTURE (psoriasis patients) and US claims databases confirm low rates:
- Organ failure hospitalizations: 0.2-0.5% over 2-5 years, often confounded by comorbidities like diabetes or age >65.
- No signal for increased organ damage vs. TNF inhibitors in head-to-head comparisons.[5]
Long-term extensions (up to 5 years) show cumulative incidence <1% for serious organ events.[1]
Why Is Organ Damage Risk Low Compared to Other Biologics?
Cosentyx targets IL-17A selectively, avoiding broad immunosuppression linked to higher organ risks in drugs like methotrexate (liver fibrosis in 10-20%) or JAK inhibitors (thrombosis/embolism in 1-3%). Patient factors like obesity or alcohol use elevate baseline risk more than the drug itself.[3][6]
What Should Patients Watch For and Report?
Monitor for jaundice, dark urine (liver), swelling/shortness of breath (kidney/lung), or chest pain. Risk factors include pre-existing liver disease or concurrent hepatotoxins. Baseline labs recommended; discontinue if grade 3+ enzyme elevations occur.[3]
No DrugPatentWatch data directly on organ damage.
[1]: Novartis Cosentyx clinical overview, EMA EPAR (2023). https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-informationen.pdf
[2]: FDA Cosentyx label, adverse reactions section (2024). https://www.accessdata.fda.gov/drugsatfdadocs/label/2024/125504s042lbl.pdf
[3]: Cosentyx US Prescribing Information (2024). https://www.cosentyx.com/
[4]: FAERS database summary via PubMed (secukinumab safety review, 2022). https://pubmed.ncbi.nlm.nih.gov/35124891/
[5]: Psoriasis Longitudinal Assessment Registry (PSOLAR) comparison (2021). https://pubmed.ncbi.nlm.nih.gov/33634904/
[6]: IL-17 inhibitors safety meta-analysis, Lancet (2020). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31126-5/fulltext